Genomic Health Inc (GHDX)

28.92
0.82 2.92
NASDAQ : Health Care
Prev Close 28.10
Open 28.20
Day Low/High 27.98 / 29.10
52 Wk Low/High 20.05 / 35.79
Volume 145.99K
Avg Volume 198.00K
Exchange NASDAQ
Shares Outstanding 33.35M
Market Cap 974.40M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Commit To Buy Genomic Health At $22.50, Earn 10.9% Annualized Using Options

Commit To Buy Genomic Health At $22.50, Earn 10.9% Annualized Using Options

Investors considering a purchase of Genomic Health Inc stock, but cautious about paying the going market price of $26.70/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2017 put at the $22.50 strike, which has a bid at the time of this writing of $1.25.

Genomic Health (GHDX): Today's Weak On High Volume Stock

Genomic Health (GHDX): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Genomic Health (GHDX) as a weak on high relative volume candidate

Genomic Health And Epic Sciences Announce Strategic Collaboration To Deliver Novel AR-V7 Liquid Biopsy Test To Predict Treatment Response In Metastatic Prostate Cancer

Genomic Health And Epic Sciences Announce Strategic Collaboration To Deliver Novel AR-V7 Liquid Biopsy Test To Predict Treatment Response In Metastatic Prostate Cancer

Validation Study Led by Memorial Sloan Kettering Cancer Center, Published in JAMA Oncology, Demonstrated Patients with AR-V7 Positive Circulating Tumor Cells Have Significantly Better Outcomes if Treated with Chemotherapy versus Hormonal Treatments

Genomic Health Launches Oncotype SEQ™ Liquid Biopsy Mutation Panel

Genomic Health Launches Oncotype SEQ™ Liquid Biopsy Mutation Panel

Genomic Health Provides Unique New Option for Non-invasive Tumor Assessment in Later-stage Disease, Transforming Cancer Care Across the Patient Journey

Nature Partner Journals Publish Five-year Outcomes Results From SEER Registry Demonstrating Oncotype DX® Accurately Identifies Early-stage Breast Cancer Patients With Excellent Survival

Nature Partner Journals Publish Five-year Outcomes Results From SEER Registry Demonstrating Oncotype DX® Accurately Identifies Early-stage Breast Cancer Patients With Excellent Survival

Study Showed Node-negative and Node-positive Patients with Low Oncotype DX® Breast Recurrence Score™ Results - the Vast Majority Treated without Chemotherapy - Had Excellent Breast Cancer Survival

Genomic Health Announces Multiple Oncotype DX® Presentations At ASCO 2016 Showcasing Industry-leading Commitment To Bringing Precision Medicine To Cancer Patients

Genomic Health Announces Multiple Oncotype DX® Presentations At ASCO 2016 Showcasing Industry-leading Commitment To Bringing Precision Medicine To Cancer Patients

Four New Analyses of SEER Registry Provide Additional Evidence that Oncotype DX Accurately Predicts Patient Outcomes in Node-negative and Node-positive Breast Cancer and Reinforce Its Value in Older Women

Genomic Health Announces Presentation Of Seven Oncotype DX® Studies At The 2016 American Society Of Clinical Oncology Annual Meeting, Including Additional Prospective Outcomes Analysis

Genomic Health Announces Presentation Of Seven Oncotype DX® Studies At The 2016 American Society Of Clinical Oncology Annual Meeting, Including Additional Prospective Outcomes Analysis

Presentations in Breast and Prostate Cancers Underscore Genomic Health's Industry-leading Commitment to Help Physicians and Patients Optimize Cancer Treatment Decisions

Genomic Health Announces Publication In Journal Of Clinical Oncology Demonstrating Oncotype DX® Predicts Late Distant Recurrence In Breast Cancer

Genomic Health Announces Publication In Journal Of Clinical Oncology Demonstrating Oncotype DX® Predicts Late Distant Recurrence In Breast Cancer

Findings Confirm that Oncotype DX May Help Identify Breast Cancer Patients with Greatest Potential to Benefit from Extended Hormonal Therapy

Genomic Health (GHDX) Strong On High Relative Volume Today

Genomic Health (GHDX) Strong On High Relative Volume Today

Trade-Ideas LLC identified Genomic Health (GHDX) as a strong on high relative volume candidate

Today's Weak On High Volume Stock: Genomic Health (GHDX)

Today's Weak On High Volume Stock: Genomic Health (GHDX)

Trade-Ideas LLC identified Genomic Health (GHDX) as a weak on high relative volume candidate

Commit To Purchase Genomic Health At $17.50, Earn 6.4% Annualized Using Options

Commit To Purchase Genomic Health At $17.50, Earn 6.4% Annualized Using Options

Investors eyeing a purchase of Genomic Health Inc shares, but tentative about paying the going market price of $23.58/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $17.50 strike, which has a bid at the time of this writing of 55 cents.

Genomic Health Announces Five-year Outcomes From International 'PlanB' Study Demonstrating The Clinical Utility Of Oncotype DX® In Node-positive And High-risk Node-negative Breast Cancer

Genomic Health Announces Five-year Outcomes From International 'PlanB' Study Demonstrating The Clinical Utility Of Oncotype DX® In Node-positive And High-risk Node-negative Breast Cancer

One of the Largest Contemporary Adjuvant Breast Cancer Trials in Europe Shows that Patients with Low Oncotype DX® Scores Can Be Spared Chemotherapy Even When Traditional Factors Indicate Higher-Risk Disease

German National Cancer Guidelines Distinguish Oncotype DX® As First And Only Multi-gene Breast Cancer Test With 1A Level Of Evidence

German National Cancer Guidelines Distinguish Oncotype DX® As First And Only Multi-gene Breast Cancer Test With 1A Level Of Evidence

Updated Guidelines Elevate Evidence following Publication of Multiple Large Prospective Outcomes Studies

Journal Of Clinical Oncology Publishes Prospective Outcomes Results From Large International Trial Using Oncotype DX®

Journal Of Clinical Oncology Publishes Prospective Outcomes Results From Large International Trial Using Oncotype DX®

New Publication of Results from 'PlanB' Study Reinforces Unique Value of Oncotype DX, the Only Multi-gene Breast Cancer Test with Prospective Outcomes Evidence in More Than 50,000 Patients

Short Interest Increases 34.5% For GHDX

Short Interest Increases 34.5% For GHDX

The most recent short interest data has been released by the NASDAQ for the 02/12/2016 settlement date, which shows a 563,388 share increase in total short interest for Genomic Health Inc , to 2,194,625, an increase of 34.54% since 01/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Relative Strength Alert For Genomic Health

Relative Strength Alert For Genomic Health

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Short Interest Drops 44.5% For GHDX

Short Interest Drops 44.5% For GHDX

The most recent short interest data has been released by the NASDAQ for the 12/31/2015 settlement date, which shows a 1,109,831 share decrease in total short interest for Genomic Health Inc , to 1,385,882, a decrease of 44.47% since 12/15/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Analysts' Actions -- Apple, American Eagle, General Motors, Under Armour and More

Analysts' Actions -- Apple, American Eagle, General Motors, Under Armour and More

Here are Monday's top research calls, including upgrades for Apple and General Motors, and downgrades for American Eagle and Under Armour.

Analysts' Actions -- Hyatt, Hess, Lockheed Martin, Smith & Wesson and More

Analysts' Actions -- Hyatt, Hess, Lockheed Martin, Smith & Wesson and More

Here are Wednesday's top research calls, including an upgrade for Lockheed Martin, and downgrades for Hyatt, Hess and Smith & Wesson.